The World Congress of Nephrology (WCN) is a global event dedicated to kidney health.
Travere at WCN
Travere Therapeutics was excited to participate in this year’s event and engage with nephrology leaders from around the world. We look forward to seeing you next year.
Program
Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results From the Pivotal Phase 3 PROTECT Trial
Speakers: Jonathan Barratt, Brad Rovin, Edward Murphy, Radko Komers, Hernán Trimarchi, Vlado Perkovic on behalf of the DUPRO Steering Committee and PROTECT investigators
Contact Your Travere MSL
Our Medical Science Liaisons (MSLs) are available to answer questions and provide support on Travere products.
Contact an MSLSparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Speakers: Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety
Speakers: Bruce Hendry, Donald Kohan, Rob Geletka, Celia Jenkinson, Shang-Chiung Chen, Patricia W. Bedard
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Speakers: Radko Komers, Rosanna Coppo, Nuhira Ahmed Masthan Ahmed, Kenneth V. Lieberman, Alex Mercer, Michelle Rheault, Moin A. Saleem, Teresa Shafer, Howard Trachtman
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Speakers: Priscila Preciado, Laura Kooienga, Robert Malecki, Alex Mercer, Nuhira Ahmed Masthan Ahmed; Presenter: Radko Komers
MA-DS-24-0021 | July 2024